Evidence map›Paper›PMID 34896453›Full record

ArticleJournal of virological methods2022

Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking.

Ran Yu, Peng Li

Abstract read
In one paragraph

Article in Journal of virological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Chemistry and Biological Activity of 11Molecules (Basel, Switzerland) · 2026
    Review
  2. A Natural Bioactive Peptide fromInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. A Review ofMolecules (Basel, Switzerland) · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ran YuDepartment of Bioengineering, Beijing Polytechnic, Daxing District, Beijing, 100176, China. Electronic address: yuran1230@hotmail.com.
Peng LiSDIC Xinkai Water Environment Investment Co., Ltd., Tongzhou District, Beijing, 101101, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel coronavirus disease has spread rapidly and caused sustained pressure on economic and medical resources to many countries. Vaccines and effective drugs are needed to fight against the epidemic. Traditional Chinese Medicine (TCM) plays an important and effective role in the treatment of COVID-19. Therefore, the active components of TCM are potential structural basis for the discovery of antiviral drugs. Through screening by molecular docking, Oleanolic acid, Tryptanthrin, Chrysophanol and Rhein were found to have better spike protein and ACE2 inhibitory activity, which could block the invasion and recognition of SARS-CoV-2 at the same time, should be investigated as antiviral candidates.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19Spike Glycoprotein, CoronavirusAntiviral AgentsGlycoproteinsHumansMolecular Docking SimulationProtein BindingSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsGlycoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2Dual antagonistsSARS-CoV-2Spike glycoprotein

Identifiers

PMID34896453
PMCPMC8660130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.